Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
Muge CevikLindsay C ThompsonCaryn UptonValéria Cavalcanti RollaMookho MalahlehaBlandina MmbagaNosipho NgubaneZamzurina Abu BakarMohammed RassoolEbrahim VariavaRodney DawsonSuzanne StaplesUmesh LallooCheryl LouwFrancesca ConradieMarika EristaviAnastasia SamoilovaSergey N SkornyakovNiyanda Elias NtinginyaFrederick HarakaGeorge PraygodHarriett Mayanja-KizzaJanice CaoiliVincent BalanagMargareth Pretti DalcolmoTimothy McHughRobert HuntPriya SolankiAnna BatesonAngela M CrookStella FabianeJuliano TimmEugene SunMelvin SpigelmanDerek J SloanStephen H Gillespienull nullPublished in: The Lancet. Infectious diseases (2024)
TB Alliance.
Keyphrases
- drug resistant
- pulmonary tuberculosis
- mycobacterium tuberculosis
- multidrug resistant
- study protocol
- open label
- acinetobacter baumannii
- clinical trial
- randomized controlled trial
- phase ii
- cross sectional
- emergency department
- phase ii study
- adverse drug
- pseudomonas aeruginosa
- drug induced
- electronic health record
- smoking cessation